<p>A Systematic Review of Health Economic Evaluation on Targeted Therapies for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Quality Evaluation</p>-Reference-Cited by-同舟云学术

A Systematic Review of Health Economic Evaluation on Targeted Therapies for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Quality Evaluation

Published:2020-06 Issue: Volume:Volume 12 Page:4357-4368
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Zhao Jie,Du Shuzhang,Zhu Yumei,Liang Yan,Lu Jingli,Chang Feng^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference45 articles.

1. What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China

2. Genomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer

3. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer

4. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Cost-Effectiveness Analyses Examining Treatments for Cachexia Syndrome;Nutrition and Cancer;2024-05-27

2. A systematic review on reporting quality of economic evaluations for negotiated glucose-lowering drugs in China national reimbursement drug list;BMC Health Services Research;2024-05-01

3. Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review;PharmacoEconomics;2024-03-15

4. Modelling Methods of Economic Evaluations of HIV Testing Strategies in Sub-Saharan Africa: A Systematic Review;Applied Health Economics and Health Policy;2023-02-28

5. The quality of published health economic evaluations on screening programs in China: a systematic review and quantitative appraisal;Expert Review of Pharmacoeconomics & Outcomes Research;2022-10-13